Eyerising Myopia Management Device
An extensive clinical trial program has proven the effectiveness of RLRL therapy and the Eyerising Myopia Management Device for the treatment of myopia.
In our landmark trial, our device was shown to achieve up to 87.7% myopia control efficacy when a patient was over 75% compliant to the treatment protocol. Children on RLRL therapy for 1 year had a 76.6% reduction in myopia progression overall compared to those who just wore spectacles. Children who continued RLRL therapy for a second year then had a 75% reduction in myopia progression compared to those who switched to glasses in the second year.